Pfenex Inc. (PFNX)
| Market Cap | 437.28M |
| Revenue (ttm) | 38.62M |
| Net Income (ttm) | -8.13M |
| Shares Out | 34.29M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | 42.37 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Sep 30, 2020 |
| Last Price | $12.75 |
| Previous Close | $12.75 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 12.74 - 12.94 |
| Day's Volume | 0 |
| 52-Week Range | 5.26 - 14.00 |
News
SAN DIEGO, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common sto...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
SAN DIEGO, Aug. 12, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Pfenex Inc.
NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc.
New York, New York--(Newsfile Corp. - August 11, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Pfenex Inc.
Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately.
Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q2 2020 Results - Earnings Call Transcript
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the...
SAN DIEGO, June 26, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today the achievement of several significant milestones across their business portfolio. Theramex, th...
SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United ...
Pfenex's (PFNX) CEO Eef Schimmelpennink on Q1 2020 Results - Earnings Call Transcript
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA review for a Therapeutic Equivalency rating for PF708 continues FDA review for a Therapeutic Equivalency rating for PF708 continues
Pfenex Inc. (PFNX) CEO Eef Schimmelpennink on Q4 2019 Results - Earnings Call Transcript
Pfenex (PFNX) delivered earnings and revenue surprises of 20.83% and 14.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organizat...
Pfenex: Update; Still A Buy For Their Therapeutic Proteins Platform
SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreem...
SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, C...
Pfenex, Inc. (PFNX) CEO Eef Schimmelpennink on Q3 2019 Results - Earnings Call Transcript
Pfenex (PFNX) delivered earnings and revenue surprises of 0.00% and 3.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks
Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately.
New Exclusive Commercialization Agreements in South Korea, Canada, and Israel
Pfenex (PFNX) news for Monday about it getting approval for its new osteoporosis treatment has PFNX stock soaring higher.
Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval
SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression ...
SAN DIEGO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression ...
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agre...
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression ...
Pfenex's (PFNX) CEO Eef Schimmelpennink on Q2 2019 Results - Earnings Call Transcript
Pfenex (PFNX) delivered earnings and revenue surprises of 4.00% and -50.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfenex has been struggling lately, but the selling pressure may be coming to an end soon.
As of late, it has definitely been a great time to be an investor in Pfenex Inc. (PFNX).
PFNX develops biosimilars to major drugs approaching patent expiry.
Pfenex's (PFNX) CEO Eef Schimmelpennink on Q1 2019 Results - Earnings Call Transcript
Pfenex (PFNX) delivered earnings and revenue surprises of 52.00% and 84.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in Pfenex.
Pfenex (PFNX) delivered earnings and revenue surprises of 29.03% and -46.64%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Wall Street analysts see Pfenex reporting a loss of 35 cents per share on revenue of $4.4 million.
About PFNX
Pfenex, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2014 |
| CEO Evert B. Schimmelpennink | Employees 88 |
| Stock Exchange NYSE American | Ticker Symbol PFNX |